MEDVi Side Effects: What to Expect and When to Get Help

By WPG Research Team · Last verified November 5, 2026 · Last updated November 5, 2026

MEDVi side effects are mostly gut problems: nausea, diarrhea, constipation, vomiting and stomach pain. They show up most when you start or raise a dose. MEDVi's main program uses compounded GLP-1 medicine, which has no MEDVi-specific side-effect studies. On brand-name labels for semaglutide and tirzepatide, nausea hit about 25% to 44% of people. Serious problems are uncommon but real.

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers.

The short answer

• Most side effects are stomach and gut related. Nausea is the one people talk about most. Diarrhea, constipation, vomiting and stomach pain come next.
• They're most likely early and after dose increases. That pattern matches what the FDA labels for Wegovy (semaglutide) and Zepbound (tirzepatide) show.
• MEDVi doesn't publish its own rates. On November 5, 2026, MEDVi's GLP storefront described compounded GLP-1 options and brand-name paths. It did not publish a MEDVi-only side-effect frequency table. The best numbers come from the FDA labels for the active ingredients.
• Some signs need fast help. Severe stomach pain that won't quit, swelling of your face or throat, or not keeping fluids down are not "just side effects."

GLP-1 safety: do not use if you or a family member has had medullary thyroid cancer (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Still deciding whether MEDVi — or any GLP-1 path — fits you? The right next step depends on your state, budget, insurance and which medicine you want.

Which MEDVi medicines can cause these side effects?

On November 5, 2026, MEDVi's GLP storefront (glp.medvi.org) listed:

MEDVi says prescriptions come only after an online visit with an independent licensed provider. It also says compounded medications are dispensed by state-licensed pharmacies and are not FDA-approved. MEDVi's own footer says it does not produce compounded medications.

For prices and plan math, see MEDVi cost, MEDVi tirzepatide and is MEDVi GLP-1 FDA approved?. For the full review, see MEDVi reviews.

The FDA warning letter (read this in context)

On February 20, 2026, the FDA issued warning letter MARCS-CMS 721455 to MEDVi, LLC (dba MEDVi). The agency said it reviewed content on medvi.io in December 2025. The letter focused on marketing and labeling claims, including:

1. Product pictures that put "MEDVi" on compounded semaglutide and tirzepatide labels in a way that suggested MEDVi was the compounder — when FDA said it is not.
2. Claims like "same active ingredient as Wegovy® and Ozempic®" and "same active ingredient as Mounjaro® and Zepbound®," which FDA said falsely implied the compounded products had been FDA-approved or evaluated for safety and effectiveness.

That is a misbranding / advertising concern under the FDCA. It is not the same thing as a clinical trial proving MEDVi's medicines are unsafe. Still, it is part of the public record, and readers comparing providers should know it. Read the letter: FDA warning letter to MEDVi (Feb 20, 2026). More on status: is MEDVi GLP-1 FDA approved?.

How common are MEDVi side effects?

MEDVi does not publish how often its members get side effects. The closest real numbers are from the FDA labels for Wegovy (semaglutide) and Zepbound (tirzepatide). These are the brand-name medicines. They are not the same as MEDVi's compounded versions.

Wegovy (semaglutide) — brand-name reference rates

Wegovy injection Table 3 rates in adults with obesity or overweight (2.4 mg once weekly vs placebo):

In those injection trials, 6.8% of people on Wegovy 2.4 mg stopped because of side effects, vs 3.2% on placebo.

Zepbound (tirzepatide) — brand-name reference rates

Zepbound Table 1 rates (5 mg, 10 mg and 15 mg vs placebo) in adults with obesity or overweight:

4.8% to 6.7% of people on Zepbound stopped because of side effects, vs 3.4% on placebo. Most who stopped did so in the first few months, mainly for gut problems.

What these tables tell you:

• Nausea is the big one across both labels.
• Many people stay on treatment. Stop rates for side effects were in the mid-single digits on these labels.
• The early months are the hardest. Dose increases are when gut symptoms spike.
• These are different trials, so the percentages are not a fair head-to-head — and they are not MEDVi's compounded products.

More: semaglutide vs tirzepatide and tirzepatide side effects.

Serious side effects to know about

These are less common, but the FDA labels for Wegovy and Zepbound warn about them. Get medical help if you notice the signs.

Extra label notes:

• Wegovy also warns about a higher resting heart rate.
• Zepbound can make birth control pills work less well. The label advises switching to a non-pill method, or adding a barrier method, for 4 weeks after you start and after each dose increase.

GLP-1 safety: do not use if you or a family member has had medullary thyroid cancer (MTC), or if you have MEN 2.

For the broader triage map, see understanding GLP-1 side effects, GLP-1 side effects and when to message your GLP-1 provider.

Are side effects different because MEDVi is often compounded?

They may be. Nobody knows for sure, because compounded versions aren't tested the way brand-name drugs are.

• Compounded is not FDA-approved. The FDA says it does not review compounded drugs for safety, effectiveness or quality before they reach patients. MEDVi's storefront says the same.
• The FDA has received reports. As of May 31, 2026, it had 990 reports of side effects linked to compounded semaglutide and more than 730 linked to compounded tirzepatide. It says many look like the brand-name side effects, and that the real number is likely higher because many compounding pharmacies don't have to report.
• Dosing mistakes are a known risk. The FDA has had reports, some needing a hospital stay, of people measuring the wrong dose of compounded injectable semaglutide from a vial.
• MEDVi ships from partner pharmacies. Its site lists partners such as Triad Rx, RedRock Pharmacy and Beaker Pharmacy. Ask your clinician which pharmacy will fill your prescription and how to measure your dose if you get a vial.

More: is compounded semaglutide safe? and the FDA's concerns with unapproved GLP-1 drugs.

What MEDVi says about support — and when to message

On November 5, 2026, MEDVi's GLP storefront marketed unlimited 24/7 support, care coaching and messaging with a dedicated team. It did not publish a detailed side-effect tip sheet or its own nausea rates on the pages we checked.

Practical steps that match standard GLP-1 care (and what other telehealth programs advise):

1. Eat smaller meals and stop when you feel full.
2. Drink fluids through the day.
3. Follow the instructions that came with your prescription.
4. Never double up a missed dose unless your clinician tells you to.
5. Don't change your dose on your own.

Message your MEDVi care team if nausea, vomiting, diarrhea or constipation keeps going or gets worse, or if you are unsure whether to take your next dose. If you cannot keep fluids down or feel dizzy, weak or dehydrated, seek prompt medical care. If you notice a serious sign in the table above, seek urgent medical help; call 911 for the emergencies listed below.

Call 911 for trouble breathing, swelling of your face, lips, tongue or throat, severe chest pain, or any emergency. Severe stomach pain that won't go away also needs fast care — it can be a sign of pancreatitis.

Want general tips that apply to any GLP-1? See how to take a GLP-1 safely and our injection-site reaction guide.

Who should talk to a doctor before MEDVi?

Tell a clinician before starting if you've had thyroid cancer, pancreatitis, gallbladder disease, severe stomach or gut disease (including gastroparesis), kidney disease, diabetic eye disease, or depression or suicidal thoughts. Also tell them if you're pregnant, trying to get pregnant, or breastfeeding.

GLP-1 safety: do not use if you or a family member has had medullary thyroid cancer (MTC), or if you have MEN 2. MEDVi — and every other GLP-1 program — is the wrong path if those apply.

MEDVi's compounded path is cash-pay. If you need insurance to pay for brand-name medicine, read does MEDVi accept insurance? and compare a brand-name route such as Ro.

Considering starting MEDVi?

For many people, GLP-1 gut side effects are uncomfortable but manageable, and they tend to ease after the first months — if you stick with the dose schedule your provider sets and message early when symptoms are hard to live with.

If you're still choosing a path:

• Want the full MEDVi review, not just side effects? Read MEDVi reviews.
• Want today's price picture? See MEDVi cost. Compare MEDVi vs TrimRx.
• Okay with compounded medicine, cash-pay, and MEDVi's support model? A licensed MEDVi-network clinician still has to decide if you qualify.

Would you rather take a medicine whose side effects were measured in large FDA trials? Brand-name Wegovy and Zepbound are FDA-approved, and Ro checks your insurance and handles prior authorization for select pens.

FAQ

What are the most common MEDVi side effects?

Nausea, diarrhea, constipation, vomiting and stomach pain — the same gut problems GLP-1 medicines are known for. MEDVi does not publish its own rates. On the brand-name Wegovy and Zepbound labels, nausea was the most common, at roughly 25% to 44% depending on the drug and dose.

How long do MEDVi side effects last?

MEDVi does not publish a timeline of its own. The FDA labels show gut symptoms are highest during dose increases. On Zepbound, most people who stopped because of side effects did so in the first few months. If symptoms aren't getting better, message your care team.

Does MEDVi cause hair loss?

MEDVi doesn't highlight hair loss on its main GLP storefront. On the brand labels, hair loss was reported in about 3% (Wegovy) and 4% to 5% (Zepbound) of people, vs about 1% on placebo. On Zepbound, hair loss was linked to weight reduction and was more common in women.

Are compounded MEDVi side effects different from Wegovy or Zepbound?

They may be. Compounded drugs are not FDA-approved and aren't studied the same way. The FDA has received hundreds of adverse-event reports for compounded semaglutide and tirzepatide, and it warns about dosing errors with vials. Ask your clinician how your specific product is measured.

Did the FDA ban MEDVi because of side effects?

No. The February 20, 2026 FDA warning letter to MEDVi was about misleading website claims (who compounds the drugs, and language that implied FDA approval). It was not a finding that MEDVi's medicines failed a safety trial. Read the letter linked above, and keep side-effect decisions with your clinician.

When should I go to the ER on MEDVi?

Call 911 for trouble breathing, swelling of your face, lips, tongue or throat, severe chest pain, or any emergency. Severe stomach pain that won't go away also needs fast care, since it can signal pancreatitis. Don't wait on a chat reply for those.

Can MEDVi GLP-1s cause low blood sugar?

The brand labels say the risk goes up if you also take insulin or certain diabetes pills (like sulfonylureas). Tell your provider about every medicine you take.

Your next step

Still not sure which GLP-1 path fits you? Take our free Find My GLP-1 Path quiz — about 2 minutes, no signup.

What we actually verified

We do not accept payment for rankings. How we compare providers is in How We Rank. Read our full MEDVi reviews.

Sources

All checked November 5, 2026.

• MEDVi: GLP storefront
• MEDVi: homepage
• FDA: Warning letter to MEDVi, LLC (MARCS-CMS 721455, Feb 20, 2026)
• FDA: Concerns with unapproved GLP-1 drugs used for weight loss
• Wegovy prescribing information
• Zepbound prescribing information